Oruka Therapeutics, Inc. (ORKA)
$89.32-$7.22 (-7.48%) Today
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 42 | 3,701,859 | $313.46M |
| Grant or award | 7 | 165,680 | |
| Option exercise | 30 | 214,916 | |
| Other acquisition / disposition | 2 | 3,596,051 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
45 Form 4 filings on record, the earliest from Nov 21, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Laura Lee Sandler - Officer | Option exercise | Common Stock | 5,000 | $7.80 | $39K | |
| Laura Lee Sandler - Officer | Open-market sale | Common Stock | 2,325 | $33.28 | $77K | |
| Laura Lee Sandler - Officer | Open-market sale | Common Stock | 2,675 | $33.81 | $90K | |
| Laura Lee Sandler - Officer | Option exercise | Employee Warrant (right to buy) | 5,000 | $0.00 | - | |
| Joana Goncalves - Officer | Option exercise | Common Stock | 3,500 | $6.84 | $24K | |
| Joana Goncalves - Officer | Option exercise | Common Stock | 3,500 | $7.80 | $27K | |
| Joana Goncalves - Officer | Open-market sale | Common Stock | 6,064 | $32.30 | $196K | |
| Joana Goncalves - Officer | Open-market sale | Common Stock | 936 | $32.78 | $31K | |
| Joana Goncalves - Officer | Option exercise | Employee Stock Option (right to buy) | 3,500 | $0.00 | - | |
| Joana Goncalves - Officer | Option exercise | Employee Warrant (right to buy) | 3,500 | $0.00 | - | |
| Joana Goncalves - Officer | Grant or award | Common Stock | 32,500 | $0.00 | - | |
| Joana Goncalves - Officer | Grant or award | Employee Stock Option (right to buy) | 130,000 | $0.00 | - | |
| Laura Lee Sandler - Officer | Grant or award | Common Stock | 32,500 | $0.00 | - | |
| Laura Lee Sandler - Officer | Grant or award | Employee Stock Option (right to buy) | 130,000 | $0.00 | - | |
| Arjun Agarwal - Officer | Grant or award | Common Stock | 17,500 | $0.00 | - | |
| Arjun Agarwal - Officer | Grant or award | Employee Stock Option (right to buy) | 70,000 | $0.00 | - | |
 Lawrence Otto Klein - Officer | Grant or award | Common Stock | 76,700 | $0.00 | - | |
| Lawrence Otto Klein - Officer | Grant or award | Employee Stock Option (right to buy) | 306,700 | $0.00 | - | |
| Paul T. Quinlan - Officer | Grant or award | Common Stock | 32,500 | $0.00 | - | |
| Paul T. Quinlan - Officer | Grant or award | Employee Stock Option (right to buy) | 130,000 | $0.00 | - | |
 Carl Dambkowski - Director | Other | Common Stock | 116,483 | $0.00 | - | |
| Joana Goncalves - Officer | Option exercise | Common Stock | 3,500 | $6.84 | $24K | |
| Joana Goncalves - Officer | Option exercise | Common Stock | 3,500 | $7.80 | $27K | |
| Joana Goncalves - Officer | Open-market sale | Common Stock | 4,381 | $31.56 | $138K | |
| Joana Goncalves - Officer | Open-market sale | Common Stock | 2,619 | $32.24 | $84K | |
| Joana Goncalves - Officer | Option exercise | Employee Stock Option (right to buy) | 3,500 | $0.00 | - | |
| Joana Goncalves - Officer | Option exercise | Employee Warrant (right to buy) | 3,500 | $0.00 | - | |
| Laura Lee Sandler - Officer | Option exercise | Common Stock | 5,000 | $7.80 | $39K | |
| Laura Lee Sandler - Officer | Open-market sale | Common Stock | 8,748 | $28.17 | $246K | |
| Laura Lee Sandler - Officer | Open-market sale | Common Stock | 3,144 | $29.08 | $91K | |
| Laura Lee Sandler - Officer | Open-market sale | Common Stock | 1,108 | $29.75 | $33K | |
| Laura Lee Sandler - Officer | Option exercise | Employee Warrant (right to buy) | 5,000 | $0.00 | - | |
| Joana Goncalves - Officer | Option exercise | Common Stock | 3,500 | $7.80 | $27K | |
| Joana Goncalves - Officer | Option exercise | Common Stock | 3,500 | $6.84 | $24K | |
| Joana Goncalves - Officer | Open-market sale | Common Stock | 641 | $28.53 | $18K | |
| Joana Goncalves - Officer | Open-market sale | Common Stock | 1,787 | $29.62 | $53K | |
| Joana Goncalves - Officer | Open-market sale | Common Stock | 1,492 | $30.70 | $46K | |
| Joana Goncalves - Officer | Open-market sale | Common Stock | 3,080 | $31.58 | $97K | |
| Joana Goncalves - Officer | Option exercise | Employee Stock Option (right to buy) | 3,500 | $0.00 | - | |
| Joana Goncalves - Officer | Option exercise | Employee Warrant (right to buy) | 3,500 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Grant or award | Common Stock | 333,340 | $15.00 | $5.00M | |
| Laura Lee Sandler - Officer | Grant or award | Employee Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Kristine M. Ball - Director | Grant or award | Stock Option (right to buy) | 17,500 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Option exercise | Common Stock | 160,000 | - | - | |
| Fairmount Funds Management LLC - Director | Option exercise | Series A Non-Voting Convertible Preferred Stock | 160 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| PAUL QUINLAN | Officer | 71,000 | $7.68M | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Oruka Therapeutics, Inc. (ORKA) had 20 insider filings in the last 90 days, with the most recent on 2026-08-25. The full record for ORKA runs to 45 Form 4 filings, the earliest from 2024-11-21. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ORKA were filed in the last 90 days.
42 insider sales of ORKA were filed in the last 90 days, totaling $313.46M.
This page tracks ORKA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ORKA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
